ArticleScientific reports2026
Strain-level molecular and infection traits are associated with differences in phage efficacy against Pseudomonas aeruginosa.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We identified and characterized a novel lytic phage, HMGUpa1, which exhibited distinct infection efficiency across five characterized P. aeruginosa clinical isolates. While all strains were susceptible to the phage, killing efficacy varied significantly, with strain 50071 showing the highest sensitivity. To explore the basis of this variability, we analyzed phage infection dynamics, host genomic features, and transcriptomic responses. Strain-specific differences in gene content and transcriptional profiles, particularly those related to virulence-associated secretion systems, RNA repair, and metabolic reprogramming, were associated with differences in phage efficacy. These findings suggest that differences in phage efficacy arise from a complex interplay of strain-specific molecular, physiological, and infection-related host traits. Together, our results highlight the importance of considering host-specific traits when developing precision-based phage therapy strategies against multidrug-resistant P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.